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Abstract
Background: Individuals with osteoporosis and recent vertebral fractures suffer from pain and impaired health-related quality
of life (HRQL). To determine whether patients with osteoporosis treated with teriparatide experienced improvement in HRQL
and pain symptoms after several months of therapy.
Methods: We retrospectively studied a sample of osteoporosis patients treated with teriparatide in a Canadian rheumatology
practice. We included patients that received teriparatide therapy with baseline and follow-up Mini-Osteoporosis Quality of Life
Questionnaire (OQLQ) data. Follow-up data was measured at three or six months. We used a paired Student's t-test to
compare baseline and follow-up measurements for each of the questionnaire's ten questions (five domains). Statistical analysis
was also repeated to only include patients who suffered a prior vertebral fracture.
Results: 57 patients were included in the study, including 47 women. The mean age was 63.8 years (standard deviation 12.1
years). About sixty five percent (37/57) had previously sustained one or more osteoporotic fractures and about 38.6% (22/57)
had suffered a prior vertebral fracture. About 44% (25/57) of individuals were taking one or more types of pain medications
regularly prior to starting therapy. At follow-up, significant improvements were observed in the OQLQ domains of pain
symptoms. This was seen when all patients on teriparatide were included, and also when only patients with prior vertebral
fractures were included. There was also an improvement in emotional functioning, relating to fear of falling at 3 months follow-
up (p = 0.019). Respondents also reported improvement in the domain of activities of daily living, relating to vacuuming at 6
months follow-up (p = 0.036), and an improvement in the leisure domain, relating to ease of traveling in the prior vertebral
fracture population at 3 months follow-up (p = 0.012). However, there was no significant improvement observed in the domains
of physical functioning. Participants also reported a decrease in need for pain medications, with 26% (15/57) requiring analgesics
at the time of follow-up.
Conclusion: Teriparatide use may be associated with improvements in HRQL in osteoporosis patients, in particular alleviation
of pain symptoms. These results were especially evident in patients with a history of vertebral fractures. These findings should
be confirmed in larger prospective studies with a suitable control group.
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Background
Osteoporosis is a disease leading to progressive decreases
in bone mineral density, decreased bone strength and
increased risk of skeletal fractures [1]. Approximately 30%
of women will have sustained at least one vertebral frac-
ture by the age of 75 [2]. There are over 700,000 incident
vertebral fractures related to osteoporosis each year in the
United States [2]. Both clinical and radiographical frac-
tures are associated with an increase mortality rate. One
study identified a 16% reduction in expected 5 year sur-
vivability [3]. Approximately 75% of patients who present
with a clinical vertebral fracture will experience chronic
pain [4]. Back pain due to vertebral fractures has a signifi-
cant impact on osteoporotic patients [4]. The number and
severity of vertebral fractures also increases the risk of
developing chronic back pain [5]. This has a significant
impact on quality of life and functional impairment on
the affected patients [6].
Conventional treatments for osteoporosis, including
bisphosphonates, selective estrogen receptor modulators
(SERMs), calcitonin and estrogen, have been shown to
reduce the rate of bone resorption and preserve bone mass
[7]. However, none of these have been shown to stimulate
new bone formation [7]. Teriparatide [recombinant
human PTH-(1–34)] is an agent shown to increase both
bone mass and bone strength [8]. In the Fracture Preven-
tion Trial (FPT), teriparatide was shown to increase lum-
bar spine and femoral neck BMD and decreased fracture
risk of both vertebral and non-vertebral fractures in post-
menopausal women with osteoporosis [2]. Aside from its
effect on BMD, teriparatide also had a positive effect on
the non-BMD determinants of bone strength [9].
In the FPT trial comparing the effect of Teriparatide 20 μg/
day to placebo in post-menopausal women, the incidence
of back pain was 17% in the treatment group, and 23% in
the placebo group [8]. Teriparatide's role in preventing
back pain in osteoporotic patients was assessed through a
meta-analysis of four completed, randomized, double-
blinded trials of teriparatide versus a comparator [2]. Nev-
itt and colleagues reported the teriparatide-treated group
had a significant reduction in new or worsening back pain
versus comparators (RR 0.73, 95% CI 0.61 to 0.87), over
a time period encompassing the clinical trial plus 30
months of post-treatment follow-up assessment [2].
The goal of this study is to determine whether patients in
every day clinical practice with osteoporosis, treated with
teriparatide, experienced improvement in HRQL and pain
symptoms after several months of therapy in a clinic set-
ting. Measuring only pain scores for these patients would
be insufficient, because aside from acute and chronic back
pain, patients with vertebral fractures also suffer from
impaired activities of daily living, anxiety and constant
fear about falling and suffering another fracture [10]. A
follow-up Mini-Osteoporosis Quality of Life Question-
naire (OQLQ) was used to quantify the patient's pain and
impact on quality of life [11]. This is primarily an explor-
atory study whose sample size is determined by the avail-
able data. In addition, this is the first study to compare
patient's HRQL data in pre and post-teriparatide therapy.
Methods
Study group and inclusion criteria
We conducted a review of osteoporosis patients who had
been placed on teriparatide therapy in a Canadian rheu-
matology practice. Two reviewers abstracted data on
demographic information, pain medications, previous
fracture history, bone mineral density and health related
quality of life (HRQL). In order to be eligible for the
study, participants must have completed a baseline and
follow-up mini-OQLQ questionnaire prior and subse-
quent to commencement of teriparatide therapy (at 3 or 6
months) (Figure 1).
Measurement of health-related quality of life
HRQL was assessed using the mini-OQLQ [11], which
was developed for clinical practice as an abbreviated form
of the original 30-item OQLQ [11]. As with the original
questionnaire, the mini-OQLQ is comprised of five
domains: symptoms, physical functioning, emotional
functioning, activities of daily living and leisure. The
mini-OQLQ has ten items, constructed from the two
items with the highest impact in each of the five domains
on the original OQLQ. It is a self-administered question-
naire that takes approximately 3 minutes to complete and
was designed to be administered in a clinic setting [11].
The OQLQ uses a 7-point scale with a score of 1 represent-
ing the worst possible function, and a score of 7 represent-
ing the best possible function. A change of approximately
0.5 within each domain is considered to be a clinical rele-
vant difference in quality of life [12,13]. The mini-OQLQ
has been validated as a sensitive measure of HRQL in oste-
oporosis patients with vertebral fracture pain. The applica-
tion of this tool by Adachi et al. [14] found patients with
vertebral fracture had higher scores on all five domains
than patients without fracture (Appendix). The Mini-
Osteopososis Quality of Life Questionnaire (OQLQ) [11]
was completed by the patient at each visit and reviewed
with the specialist or nurse clinician. Patients were given
the mini-OQLQ prior to initiation of teriparatide and at 3
and/or 6 months follow-up.
Statistical analyses
As mentioned earlier, this is an exploratory study whose
sample size is primarily determined by the available data.
The results of this study will provide us with some further
insight about the potential effect of teriparatide on health-
related quality of life in primary care of patients with oste-BMC Musculoskeletal Disorders 2008, 9:151 http://www.biomedcentral.com/1471-2474/9/151
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oporosis which can be explored further in major study. All
patients with a follow-up visit at either 3 months or 6
months were compliant with their treatment.
Descriptive data were reported as means (standard devia-
tions [SD]) or median [minimum [min] – maximum
[max]) for continuous or discrete variables and count
(percentage) for categorical variables. We used the paired
Student's T-tests to compare scores on questions of the
mini OQLQ prior to and during teriparatide treatment.
Analysis was performed comparing the baseline scores to
both the follow-up results after 3 and 6 months of ther-
Enrollment of 105 patients on teriparatide therapy were screened for eligibility Figure 1
Enrollment of 105 patients on teriparatide therapy were screened for eligibility. 48 patients were excluded: 2 had 
not completed baseline questionnaires, 2 withdrew prior ro follow-up due to adverse effects, and 44 had no follow-up data at 
3 or 6 months for the most part because they did not have a follow-up appointment at these points.
18 Patients  18 Patients 
with a  with a 
vertebral vertebral
fracture fracture
44 patients with baseline and 3 or 6 
month follow up data
2 patients had no baseline data
2 patients withdrew prior to 3 to 6 
month follow up due to adverse effects
57 patients had no follow up data 
at 3 or 6 months
105 teriperatide patients screened
6 Month  6 Month 
Follow Follow- -up up
3 Month  3 Month 
Follow Follow- -up up
18 Patients  18 Patients 
without without
vertebral vertebral
fractures fractures
12 Patients  12 Patients 
without without
vertebral vertebral
fractures fractures
27 Patients  27 Patients 
with a  with a 
vertebral vertebral
fracture fractureBMC Musculoskeletal Disorders 2008, 9:151 http://www.biomedcentral.com/1471-2474/9/151
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apy. Patients with a prior vertebral fracture were separated
and reanalyzed to assess if teriparatide had a greater effect
on those with a pre-existing vertebral fracture and/or back
pain. We used normal probability plots to assess the Nor-
mality assumption. The criterion for statistical signifi-
cance was set apriori at alpha = 0.05. We used SPSS 12.0
for all statistical analyses.
Results
Participant characteristics
The study sample included 57 participants, with
82.5% (n = 47) being female (Table 1). The mean age
was 63.9 (SD = 12.1). From the 57 total participants,
45 received their QOL assessment at the 6 month fol-
low up period, and 30 participants were evaluated at
the 3-month follow up period. A majority of patients
(64.9%) reported that they had previously suffered at
least one vertebral or non-vertebral fracture. Vertebral
fractures were defined as patients with clinical frac-
tures with x-ray report confirmation. Among the
patients evaluated at the 6 month follow-up point, 27
of the 45 patients had suffered a previous vertebral
fracture, and 18 of the 30 patients evaluated at the 3
month point suffered a prior vertebral fracture. At
baseline, 43.9% of participants (n = 25) reported tak-
ing a pain medication for pre-existing back pain. The
distribution of different classes of pain medications
taken were listed in table 2. The remaining patients
with no history of fractures were treated with teri-
paratide because of severe osteoporosis with subse-
quent lack of improvement on bisphosphonate
therapy.
HRQL domains and teriparatide
The mini-ORQL can be divided into five distinct domains
relating to HRQ: symptoms (Q1, Q2), emotional function
(Q3, Q4), physical function (Q5, Q6), activities of daily
living (Q7, Q8), and leisure (Q9, Q10). Each question
was analyzed individually and grouped according to the
domains that they represent (Table 3). The analysis was
repeated after only including patients with a prior verte-
bral fracture (Table 4).
Symptoms
The HRQL domain of symptoms showed significant
decreases post-teriparatide therapy for both questions that
addressed it. Data are expressed as (mean; standard devi-
ation). For patients with 3 month follow-up data, the
baseline data for Q1 (4.400; 1.850) was reduced in fol-
low-up data (3.533; 1.833) (p = 0.028), and for patients
with 6 month data, the baseline values of (3.911; 1,905)
was reduced to (3.311; 1.607) (p = 0.039). Similarly base-
line data for Q2 (3.756; 2.112); was lower in the 6 month
follow-up data (3.200; 1.646)) (p = 0.022). These results
were also evident when only patients with only prior ver-
tebral fractures were included. At 3 month follow up, Q1
decreased from (5.111; 1.641) to (4.444; 1.756) (p =
0.005) and at 6 month follow-up, Q1 decreased from
(4.37; 2.003) to (3.593; 1.738) (p = 0.007). Similarly after
6 months, Q2 also decreased from (4.593; 1.907) to
(3.667; 1.710) (p = 0.009) for the vertebral fracture group.
Emotional functioning
The questions addressing emotional functioning also
demonstrated a significant improvement in Q4. The base-
Table 1: Demographic baseline information of patients * Values are mean (standard deviation)
Variable Number of participants (total = 57) Characteristics of the patients
Age (years)* 57 63.8 (12.1)
Height (cm) at baseline* 53 160.8 (9.5)
Weight (kg) at baseline* 53 63.3 (15.7)
DXA lumbar spine BMD (g/cm2)* 54 .8298 (.1657)
DXA hip BMD (g/cm2)* 51 .6742 (.1129)
Female gender 47 82.50%
Pain meds at baseline 25 43.86%
Vertebral fracture history (one or more) 22 38.60%
Multiple fracture history (vertebral or non-vertebral) 28 49.10%
History of any type of prior fracture (one of more) 37 64.90%BMC Musculoskeletal Disorders 2008, 9:151 http://www.biomedcentral.com/1471-2474/9/151
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line for Q4 (3.600; 1.940) was lower after 6 months of
therapy (3.000; 2.034) (p = 0.019). However, this was not
evident when only considering patients with prior verte-
bral fractures. Q3 did not reveal any significant improve-
ment after initiating teriparatide.
Physical functioning
Data for the physical functioning domain did not show a
significant improvement in either questions, and there
was no difference when only considering patients with
prior vertebral fractures.
Activities of daily living
Question 7 which assessed the difficulty of vacuuming
showed a significant improvement at the 6 month follow-
up point (3.133; 2.659) to (2.333; 2.558) (p = 0.036) but
there was no significant. However, this change was not
evident when only considering patients with prior verte-
bral fractures. Question 8 did not reveal and significant
improvement.
Leisure
Question 9, which assessed the patient's difficulty in trav-
elling showed a significant improvement after 3 months
of therapy in the vertebral fracture patients. The scores
decreased from (3.444; 2.332) to (2.500; 2.307) (p =
0.012). Q10 did not reveal any significant improvement
after initiating teriparatide.
Discussion
Vertebral fractures are an important and common cause of
morbidity in osteoporotic patients [15]. Vertebral frac-
Table 2: Comparison of pain medication use by patients at time of baseline and follow-up.
Before treatment At time of follow-up
NSAIDS 54
Narcotics 10 6
Over the counter analgesia 95
Amitryptyline 10
• Pain medication information was recorded at either the 3 month or 6 month period, whichever was available. If data was available at both follow-
up periods, the later one was used.
Table 3: Baseline and follow-up mean scores of patients at 3 months and 6 months follow-up (includes patients with and withour prior 
vertebral fractures)
Domain Question Baseline Mean 
(SD)-3 Mth 
patients
Baseline Mean 
(SD)-6 Mth 
patients
3 Month 
Follow-up 
(SD)
6 Month 
Follow-up 
(SD)
Sig (2 tailed) 
3 Mths
Sig (2 tailed) 
6 mths
Symptoms Q1 4.400 (1.850) 3.911 (1.905) 3.533 (1.833) 3.311 (1.607) 0.028 0.039
Q2 4.233 (1.960) 3.756 (2.112) 3.967 (1.921) 3.200 (1.646) 0.475 0.022
Emotional 
Functioning
Q3 3.633 (2.141) 2.800 (2.052) 3.267 (2.033) 2.578 (1.948) 0.102 0.488
Q4 3.600 (1.940) 2.889 (1.886) 3.000 (2.034) 2.756 (1.956) 0.019 0.641
Physical 
Functioning
Q5 3.933 (2.016) 3.600 (2.168) 3.967 (1.903) 3.267 (2.093) 0.882 0.092
Q6 3.867 (2.080) 3.267 (2.230) 3.600 (2.175) 2.911(2.172) 0.428 0.139
ADLs Q7 3.367 (2.632) 3.133 (2.659) 2.933 (2.406) 2.333 (2.558) 0.227 0.036
Q8 3.467 (2.417) 3.067 (2.416) 2.967 (2.236) 2.489 (2.351) 0.083 0.106
Leisure Q9 3.100 (2.234) 2.378 (2.167) 2.200 (2.091) 2.244 (1.897) 0.001 0.679
Q10 2.733 (2.586) 2.333 (2.421) 2.500 (2.330) 2.222 (2.245) 0.415 0.628BMC Musculoskeletal Disorders 2008, 9:151 http://www.biomedcentral.com/1471-2474/9/151
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tures are among the top health conditions accounting for
length of hospital stay, and added significantly to the
length of stay to patients admitted for other medical prob-
lems [16]. Aside from the physical limitations suffered by
these patients, chronic back pain has a significant impact
on the patient's quality of life [17]. Patients suffering from
vertebral fractures often have impaired physical function-
ing, limited activities of daily living, limited leisure and
recreational activities, and significant emotional distress
[11]. The use of teriparatide in the treatment of postmen-
opausal osteoporosis revealed a decrease in the risk of
both vertebral and non-vertebral fractures, along with a
significant increase in vertebral, femoral neck, and total
body-bone mineral density [8]. The goal of our study is to
evaluate the effect of teriparatide treatment on the risk of
back pain and health related quality of life in osteoporotic
patients in a clinical practice setting. Studies in the past
have investigated the effect of teriparatide on back pain
risk in a randomized control trial setting [2]. Nevitt and
associates' systematic review identified five randomized
clinical trials (RCTs) that evaluated prevention of back
pain in teriparatide treated osteoporotic patients. In con-
trast, our study investigates patients with pre-existing back
pain, and we measured the improvement in pain severity
and effect on quality of life after initiating teriparatide
therapy. Also, the incidence of back pain was not the pri-
mary outcome in any of these studies, with new vertebral
fractures (n = 1) or changes in bone mineral density (n =
4) as the primary outcomes [2]. Back pain data were col-
lected through spontaneous reporting by patients as
adverse events. The conclusion of the meta-analysis was
that patients randomized to teriparatide had a reduced
risk of new or worsening back pain compared to patients
randomized to placebo or anti-resorptive therapies [2].
RCTs have several disadvantages. Although RCTs are able
to demonstrate the efficacy of a therapy, it has certain lim-
itations in demonstrating the therapy's effectiveness in a
real world patient population. Firstly, patients in RCTs
represent a very homogeneous patient population that
may not reflect the target patient population. These
patients are also self selected, therefore they have higher
likelihood of having a high compliance rate to treatment
[18].
Analysis of our HRQL data in our patients' pre and post-
teriparatide therapy revealed statistically significant
improvements predominantly in the domain of symp-
toms, but there were also improvements in the domains
of emotional functioning, ADLS, and leisure. The symp-
toms domain inquired about discomfort/distress related
to pain, while the emotional functioning domain
addressed the patients' fears of two major complications,
fractures and falling. A reduction in the symptoms
domain indicates that patients who received teriparatide
therapy went on to experience less pain than prior to ther-
apy. In addition, there was a decrease in patients requiring
analgesics after treatment (a drop from 44% to 26%
(Table 4). Analgesia use was identified using patient infor-
Table 4: Baseline and follow-up mean scores of patients with prior vertebral fractures (3 months and 6 months follow-up)
Domain Question Baseline Mean 
(SD)-3 Mth 
patients
Baseline Mean 
(SD)-6 Mth 
patients
3 Month 
Follow-up 
(SD)
6 Month 
Follow-up 
(SD)
Sig (2 tailed) 
3 Mths
Sig (2 tailed) 
6 mths
Symptoms Q1 5.111 (1.641) 4.37 (2.003) 3.667 (1.782) 3.593 (1.738) 0.005 0.007
Q2 5.000 (1.749) 4.593 (1.907) 4.444 (1.756) 3.667 (1.710) 0.243 0.009
Emotional 
Functioning
Q3 3.889 (2.398) 2.852 (2.282) 3.667 (2.086) 3.222 (2.136) 0.495 0.401
Q4 3.722 (2.109) 2.926 (1.817) 3.278 (2.321) 3.259 (2.030) 0.238 0.39
Physical 
Functioning
Q5 5.000 (1.495) 4.111 (2.190) 4.556 (1.756) 3.815 (2.185) 0.149 0.235
Q6 4.667 (1.782) 3.963 (2.192) 4.333 (1.940) 3.407 (2.275) 0.269 0.13
ADLs Q7 3.944 (1.667) 3.667 (2.815) 3.444 (2.617) 2.963 (2.766) 0.291 0.124
Q8 4.111 (2.349) 3.667 (2.617) 3.500 (2.282) 2.778 (2.486) 0.135 0.053
Leisure Q9 3.444 (2.332) 2.630 (2.372) 2.500 (2.307) 2.370 (1.844) 0.012 0.571
Q10 3.556 (2.749) 2.889 (2.651) 3.000 (2.521) 2.519 (2.359) 0.221 0.225BMC Musculoskeletal Disorders 2008, 9:151 http://www.biomedcentral.com/1471-2474/9/151
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mation questionnaires. Based on the data collected, there
is a suggestion that teriparatide use may decrease improve
the need for analgesia. However, many of the patients
who completed the questionnaire did not indicate the
specific dosage of the analgesia they were taking. There-
fore, we were unable to assess if there was a decrease in fre-
quency or potency in analgesia use. An improvement in
emotional functioning scores suggests that patients
treated with teriparatide had less fear of falls than they
experienced before receiving the medication. Therefore
patients had less pain discomfort at both three to six
months after being started on teriparatide, and these
trends were also seen when only patients with a history of
vertebral fractures were included. There are several limita-
tions to our study, including missing data resulting in
exclusion of some participants, and lack of a control
group.
Conclusion
In conclusion, previous studies have demonstrated that
teriparatide therapy results in decreased fractures and pain
symptoms in patients with osteoporosis, and may be par-
ticularly beneficial in patients with a history of vertebral
fractures. There was a greater statistical significance in the
vertebral fracture population than in the total population.
Patients also appeared to benefit quickly after therapy was
initiated, as a significant difference was evident even at the
3 month follow-up period for certain domains in the
HRQL survey. In this study, we have confirmed that
patients with osteoporosis treated with teriparatide expe-
rience improvements in pain symptoms. Furthermore,
certain aspects of emotional functioning, activities of
daily living, and leisure activities appears to improve with
therapy. Our findings need to be validated in a larger pro-
spective study with a suitable control group.
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Appendix: Shortened Osteoporosis Quality of 
Life Questionnaire
1) How much distress or discomfort have you had
because of pain in the last two weeks?
2) How much distress or discomfort you had in last two
weeks because it had been painful to stand for a long time
3) How often in the last two weeks have you felt afraid of
fractures?
4) How often in the last two weeks have you felt afraid of
falling?
5) How difficult has it been for you to lift things in the last
two weeks?
6) How difficult has it been for you to carry things in the
last two weeks, because of back problems due to oste-
oporosis?
7) How difficult has it been for you to vaccum in the last
two weeks?
8) How difficult has it been for you to housework in the
last two weeks?
9) How difficult has it been for you to travel in the last two
weeks?
10) How difficult has it been for you to take the type of
vacation or holiday you enjoy because of your back prob-
lems due to osteoporosis
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